Abstract:Objective To observe and evaluate the efficacy and safety of palonosetron hydrochloride capsules made in China for prevention of chemotherapy-induced nausea and vomiting. Methods This study was performed as a multicenter,randomized,double-blind control clinical trial. The patients were randomized to administer palonosetron hydrochloride capsule( 0. 5mg) and a simulator of granisetron dispersible tablet( experimental group),or a granisetron dispersible tablet( 1mg) and a simulator of palonosetron( control group),each administered 1 hour before initiation of moderate emetogenic chemotherapy. After 12 h for chemotherapy,experimental group were administered a simulator of granisetron dispersible tablet and control group were administered a granisetron dispersible tablet( 1mg). The acute emetic episodes,delayed emetic episodes,nausea,physical status and VAS scores was recorded,administer rescue medication( granisetron combined with dexamethasone) was taken if patients needed. Results A total of 240 patients from seven clinical research centers in China were randomized to the clinical trial with 122 patients in experimental group and 118 patients in control group. The proportion of patients with emetic episodes overall periods( 0-7days) was lower in experimental group than in control group( 21. 31% vs.33. 33%,P=0. 0422). The proportion of patients with no emetic episodes during the 24 h after chemotherapy administration( acute period) between experimental group and control group was no significant difference through full analysis set( 86. 89% vs. 85. 47%,P =0. 8338),and the proportion of patients with no emetic episodes during delay( 24h-7days post-chemotherapy) between experimental group and control group was significant difference through per-protocol set analysis( 74. 38% vs. 61. 54%,P = 0. 0490). The average vomiting times of experimental group and control group were 0. 15±0. 52 and 0. 31±0. 68 respectively in second day of chemotherapy( P = 0. 0090). There were no significant difference for rates of grade 0 nausea and PS scores between two groups in 1-5 days of chemotherapy( P0. 05),except to VAS scores in 2-4 days of chemotherapy( P0. 05). The adverse reactions of experimental group and control group included constipation( 2 cases),total bilirubin( 2 cases) and constipation( 4 cases),drug dermatitis( 1 case),respectively. The adverse reaction rates between two groups were 3. 28% and 4. 24% respectively( P0. 05). Conclusion Palonosetron hydrochloride capsule is similar to granisetron for preventing chemotherapy-induced acute nausea and vomiting,and superior to granisetron for delayed nausea and vomiting. Palonosetron hydrochloride capsule is safe and convenient administration.

Therapeutic Effects Of Palonosetron Plus Tropisetron On Chemotherapy-Induced Nausea And Vomiting

The Effect of Palonosetron Hydrochloride in the Prevention of Chemotherapy-Induced Moderate and Severe Nausea and Vomiting

Efficacy and Safety of Palonosetron Versus Tropisetron in the Prevention of Highly Emetogenic Chemotherapy-Induced Acute and Delayed Vomiting in Chinese Cancer Patients

Palonosetron for Prevention of Acute and Delayed Nausea and Vomiting in Non-Small-Cell Lung Carcinoma Patients

A Clinical Study of Palonosetron in Prevention of Chemotherapy-related Nausea and Vomiting in Patients with Breast Cancer

Effect of Palonosetron in Preventing Chemotherapy-Induced Vomiting

Comparison of Tropisetron Versus Tropisetron Plus Methylprednisolone in Prevention of Chemotherapy Induced Emesis

A Narrative Review of Tropisetron and Palonosetron for the Control of Chemotherapy-Induced Nausea and Vomiting

Applying palonosetron to prevent nausea and vomiting caused by chemotherapy with nimustine in brain glioma patients

Single-dose Tropisetron for prevention of Cisplatin-induced emesis

Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population

Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: A meta-analysis

The Efficacy of Palonosetron for Prevention of Concurrent Radiochemotherapy Induced Nausea and Vomit in Patients with Locally Advanced Nasopharyngeal Carcinoma

Comparison of different administration methods of aprepitant and tropisetron in preventing vomiting induced by cisplatin chemotherapy in treatment of advanced lung cancer

Comparison of antienetic efficacy between palonosetron and ondansetron in patients treated with moderately emetogenic chemotherapy

The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial.

Phase III Randomized Trial of Palonosetron and Dexamethasone with or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer

A Multicenter,double-Blind,randomized Control Clinical Trail of Palonosetron Hydrochloride Capsules for Prevention of Chemotherapy-Induced Nausea and Vomiting

Efficacy of Medroxyprogesterone Acetate Combined with Ondansetron on Preventing Vomiting Induced by Chemtherapy for Non-Small Cell Lung Cancer

The Clinical Study of Tropisetron Capsule in the Prevention of Nausea and Vomiting Induced by Anti-cancer Drugs

Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy